At the news
? BULLISHIMPACT 7/10 8-K filed Jul 6, 2026 at 21:55 ET
Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing a total equity value of $10.0 billion ($8.8 billion net of cash). The deal adds PALSONIFY (approved, launched oral therapy for acromegaly) and atumelnant (Phase 3 oral ACTH receptor antagonist for congenital adrenal hyperplasia) to Vertex's pipeline, which it expects to generate over $5 billion in combined peak annual revenue. Vertex funded the transaction with cash on hand and a fully committed $4.5 billion bridge financing facility from Bank of America and Morgan Stanley; the deal is expected to close in Q3 2026 and become accretive to non-GAAP operating income in 2029.
- Vertex acquired Crinetics for $85.00 per share in cash, with a $10.0B equity valuation ($8.8B net of cash).
- The deal adds PALSONIFY, the first and only once-daily oral therapy for acromegaly (launched Oct. 2025, FDA and EMA approved), and atumelnant, a Phase 3 oral ACTH receptor antagonist for congenital adrenal hyperplasia (CAH).
- Vertex expects the combined assets to generate over $5 billion in annual peak revenue and the deal to become accretive to non-GAAP operating income in 2029.
- The merger is expected to close in Q3 2026, subject to Crinetics shareholder approval, HSR clearance, and other customary conditions.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access